These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26220087)

  • 1. Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma.
    Miller MR; Ma D; Schappet J; Breheny P; Mott SL; Bannick N; Askeland E; Brown J; Henry MD
    Mol Cancer; 2015 Jul; 14():141. PubMed ID: 26220087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glycosyltransferase LARGE2 is repressed by Snail and ZEB1 in prostate cancer.
    Huang Q; Miller MR; Schappet J; Henry MD
    Cancer Biol Ther; 2015; 16(1):125-36. PubMed ID: 25455932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.
    Esser AK; Miller MR; Huang Q; Meier MM; Beltran-Valero de Bernabé D; Stipp CS; Campbell KP; Lynch CF; Smith BJ; Cohen MB; Henry MD
    J Biol Chem; 2013 Jan; 288(4):2132-42. PubMed ID: 23223448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer.
    Dietinger V; García de Durango CR; Wiechmann S; Boos SL; Michl M; Neumann J; Hermeking H; Kuster B; Jung P
    Cell Commun Signal; 2020 Jun; 18(1):102. PubMed ID: 32586342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma.
    Sgambato A; Camerini A; Amoroso D; Genovese G; De Luca F; Cecchi M; Migaldi M; Rettino A; Valsuani C; Tartarelli G; Donati S; Siclari O; Rossi G; Cittadini A
    Cancer Biol Ther; 2007 Dec; 6(12):1840-6. PubMed ID: 18087214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SATB1 is Down-regulated in Clear Cell Renal Cell Carcinoma and Correlates with miR-21-5p Overexpression and Poor Prognosis.
    Kowalczyk AE; Krazinski BE; Godlewski J; Grzegrzolka J; Kiewisz J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Dziegiel P; Kmiec Z
    Cancer Genomics Proteomics; 2016; 13(3):209-17. PubMed ID: 27107063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
    Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
    Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies.
    Grewal PK; McLaughlan JM; Moore CJ; Browning CA; Hewitt JE
    Glycobiology; 2005 Oct; 15(10):912-23. PubMed ID: 15958417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
    Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.
    Zheng J; Wang L; Peng Z; Yang Y; Feng D; He J
    EBioMedicine; 2017 Feb; 15():62-72. PubMed ID: 27993630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
    Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T
    J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
    Du P; Ye L; Yang Y; Jiang WG
    Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.